Photo taken from ESMO/LinkedIn
May 18, 2024, 01:12
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn:
“Results from the IMpassion132 trial presented at ESMO Breast 24 reveal that adding atezolizumab to chemotherapy does not improve overall survival in patients with advanced triple-negative breast cancer (TNBC) relapsing within 12 months after initial treatment.
However, according to Carmen Criscitiello, the higher objective response rate achieved with atezolizumab suggests that at least some patients could benefit from it, and this highlights the importance of individualised treatment approaches.
Read more in the ESMO Daily Reporter article.”
Source: ESMO/LinkedIn
OncoDaily
Advanced triple-negative breast cancer (TNBC)
atezolizumab
cancer
carmen criscitiello
chemotherapy
ESMO Breast 24
ESMO Daily Reporter
European Society for Medical Oncology (ESMO)
IMpassion132 trial
Individualized treatment approaches
objective response rate
OncoDaily
Oncology
overall survival
Relapse
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46